Elysium Index: An Accessible Entry Point to Epigenetic Age Testing
Backed by Nobel Prize-winning science and priced at $299, the Elysium Index measures biological age through DNA methylation. Is this the most accessible on-ramp to epigenetic health tracking?
Presented By Our Partners
The concept that aging can be measured, not just experienced, is one of the most consequential ideas in modern longevity science. In 2018, Morgan Levine and Steve Horvath at UCLA published a study in the journal Aging that developed DNAm PhenoAge, an epigenetic biomarker that outperformed all previous measures in predicting all-cause mortality, cancer, healthspan, and Alzheimer’s disease by integrating clinical phenotypic data with DNA methylation patterns. The finding confirmed what a growing body of research had been suggesting: biological age, derived from molecular markers rather than calendar years, captures health trajectory information that no single blood test, imaging study, or physical exam can provide alone. Elysium Health, a supplement company co-founded by Leonard Guarente, a pioneering aging researcher at MIT, launched the Elysium Index as a consumer-accessible biological age test built on this methylation science. The product sits at the intersection of two trends: the democratization of epigenetic testing and the growing consumer demand for quantified longevity metrics. At $299, it positions itself as a more affordable alternative to TruDiagnostic’s $499 TruAge Complete while leveraging scientific partnerships that trace back to some of the foundational work in aging biology.
What Is the Elysium Index?
The Elysium Index is an at-home saliva-based biological age test that uses DNA methylation analysis to estimate how old your body appears at the molecular level relative to your chronological age. Users collect a saliva sample using the provided kit, mail it to Elysium’s CLIA-certified partner laboratory, and receive results through a secure online dashboard within approximately 4 to 8 weeks.
The report provides a biological age estimate, a pace of aging metric (indicating whether you are aging faster or slower than expected), and a cumulative rate of aging score that reflects long-term trends. Results are contextualized against Elysium’s reference population database, allowing users to see how their biological age compares to others of the same chronological age. The dashboard includes basic guidance on lifestyle factors associated with epigenetic age modification, including nutrition, exercise, sleep, and stress management recommendations.
Elysium Health also sells a supplement line, most notably Basis (containing nicotinamide riboside and pterostilbene), and the Index test is positioned partially as a measurement tool for users who want to track the biological impact of these supplements over time. However, the test functions independently and does not require purchase of any Elysium supplement.
The Science Behind It: DNA Methylation as a Window into Biological Aging
The Elysium Index is built on the same foundational science that underpins all epigenetic age testing: the observation that DNA methylation patterns at specific CpG sites change in predictable ways as organisms age, and that the rate of these changes correlates with health outcomes and mortality risk.
The 2018 DNAm PhenoAge study by Levine et al. demonstrated that epigenetic biomarkers could predict all-cause mortality, cancer, and functional decline more accurately than previous clock algorithms by incorporating clinical measures of phenotypic aging into the training model. The study used data from over 9,000 individuals and validated its predictions across multiple independent cohorts. A 2021 study by McCrory et al. in The Journals of Gerontology further established GrimAge as the strongest predictor of clinical outcomes, predicting mortality, frailty, walking speed, and cognitive performance in 490 participants followed for up to 10 years, outperforming three other epigenetic clocks in head-to-head comparison.
A 2022 review by Li et al. in the Journal of Internal Medicine argued that the field must shift from chasing increasingly accurate age prediction toward understanding the mechanistic links between epigenetic changes and the physiological processes of aging. The review highlighted that certain methylation sites and their associated genes show strong potential as biomarkers for neurodegenerative disease and cancer, and that longitudinal methylation studies are revealing epigenetic signatures of type 1 diabetes, psychotic experiences, and other conditions years before clinical onset.
Elysium’s specific algorithmic implementation draws on these published clock methodologies, though the company has not disclosed the exact CpG sites or weighting used in its proprietary algorithm. The scientific advisory board includes researchers who contributed to foundational aging biology, and the test is processed in a CLIA-certified laboratory, providing quality assurance. However, unlike TruDiagnostic, Elysium does not specify which named clock algorithms (Horvath, GrimAge, DunedinPACE) are included in its report. That is the science. Here is how Elysium applies it.
What the Elysium Index Does Well
The most immediate advantage is pricing. At $299, the Elysium Index costs 40% less than TruDiagnostic’s TruAge Complete ($499), making it the most affordable established epigenetic age test that provides a pace of aging metric alongside a biological age estimate. For consumers who want to enter the world of biological age measurement without a $500 commitment, Elysium provides a credible entry point.
The saliva-based collection method is a practical advantage for users who prefer to avoid finger-prick blood collection. While blood-based methylation analysis is generally considered more robust (blood contains a richer and more standardized cellular population than saliva), saliva collection is painless, requires no special handling, and has been validated as a viable sample type for epigenetic analysis.
Featured Partner
Invest in the Infrastructure Behind Modern Medicine
As healthcare expands beyond hospital walls, the buildings and campuses supporting that shift are generating compelling returns for investors who move early. The Healthcare Real Estate Fund offers qualified investors direct access to a curated portfolio of medical office, outpatient, and specialty care facilities.
Learn More →
The dashboard presentation is clean and consumer-friendly, translating complex methylation data into intuitive metrics: biological age, pace of aging, and cumulative rate of aging. For users who are new to epigenetic testing and do not need the multi-algorithm depth that TruDiagnostic provides, this simplified presentation may be preferable. The integration with Elysium’s supplement line, while commercially motivated, provides a convenient pathway for users who want to test, intervene, and retest within a single ecosystem.
Pricing, Access, and Practical Realities
The Elysium Index costs $299 per test with no subscription required. Elysium periodically offers multi-test packages at reduced per-test pricing for users planning longitudinal tracking. The company recommends retesting every 3 to 6 months, similar to TruDiagnostic’s recommendation, to track the impact of lifestyle or supplement interventions over time.
No physician order is required. Results are delivered within approximately 4 to 8 weeks. The test is not currently listed as HSA or FSA eligible, though users should verify with their specific plan administrators. Elysium Index is not FDA cleared as a diagnostic device; results are classified as informational wellness data.
Elysium Health is a supplement company first and a testing company second. Users should be aware of this business context when evaluating the objectivity of the test’s results and any accompanying lifestyle or supplement recommendations. The test functions independently of Elysium’s supplement products, and users are under no obligation to purchase supplements to use or benefit from the biological age data.
Who the Elysium Index Is Best For
The Elysium Index is ideal for longevity-curious consumers who want their first biological age measurement at an accessible price point. It suits individuals who are implementing lifestyle changes and want a baseline measurement before tracking progress over time. Users who prefer saliva collection over blood collection will find the sample process easier. Those already using Elysium’s Basis supplement who want to measure its biological impact have a natural pairing between product and test.
Those who should consider alternatives include users who want the most comprehensive epigenetic analysis available, as TruDiagnostic TruAge Complete provides more algorithms (OMICmAge, DunedinPACE, GrimAge, PhenoAge, Horvath), organ-specific aging data, and immune cell composition analysis for $200 more. Anyone seeking genetic (not epigenetic) testing needs a different product entirely, such as 23andMe, Nebula Genomics, or Color Health. Users who want a fundamentally different approach to biological age measurement should consider GlycanAge, which uses glycan-based immune system aging markers rather than DNA methylation. Individuals who need diagnostic-grade results for clinical decision-making should work with a healthcare provider who can order clinical epigenetic testing if available.
How the Elysium Index Compares
TruDiagnostic TruAge Complete ($499) is the primary competitor and the more comprehensive product. TruDiagnostic’s advantages include multiple named clock algorithms, organ system ages, DunedinPACE pace-of-aging measurement, immune cell analysis, and a deeper research validation track record with over 15 peer-reviewed publications. Elysium’s advantages are its lower price, saliva-based collection, and simpler user experience. For users who want depth, TruDiagnostic wins. For users who want accessibility, Elysium wins.
GlycanAge ($299 to $499) measures biological age through glycan patterns on immunoglobulin G antibodies rather than DNA methylation, providing a complementary view of immune system aging. myDNAge ($299 to $499) from Zymo Research offers the original Horvath clock with the option of urine-based sample collection. Chronomics ($299 to $499) provides methylation-based biological age with a focus on longitudinal lifestyle tracking. All four competitors operate in the $299 to $499 range, with differentiation based on methodology (methylation vs. glycan), algorithm selection, and supplementary data included in the report.
Limitations and Open Questions
Elysium does not disclose which specific epigenetic clock algorithms underlie its biological age calculation. This lack of algorithmic transparency makes it difficult for users and researchers to compare Elysium’s results directly against published clock data or against results from competitors like TruDiagnostic that specify their algorithms. Without knowing whether the results reflect Horvath, PhenoAge, GrimAge, or a proprietary composite, users cannot evaluate which dimension of aging is being measured.
Saliva-based methylation analysis, while validated, introduces more cellular heterogeneity than blood-based analysis. Saliva contains a mixture of epithelial cells, immune cells, and microbial DNA, and the cellular composition can vary based on oral health, hydration status, and recent eating or drinking. This variability may introduce noise that reduces test-to-test consistency, which is particularly relevant for longitudinal tracking where small changes matter.
The connection to Elysium’s supplement business raises questions about potential conflicts of interest. While the test functions independently, users should be aware that the company has a financial incentive to demonstrate that its supplements produce favorable biological age changes. No peer-reviewed, independently conducted study has demonstrated that Elysium’s Basis supplement produces statistically significant reductions in epigenetic age. The standard cautions about epigenetic testing apply: the field is young, individual-level precision has meaningful error margins (typically 3 to 5 years), and the causal link between methylation changes and lifespan extension remains unproven.
What This Means for Your Health
Measuring biological age is becoming as fundamental to longevity optimization as measuring cholesterol or blood pressure. The research is clear that epigenetic age acceleration predicts mortality, disease, and functional decline independently of traditional risk factors. Within Healthcare Discovery‘s longevity framework, epigenetic age testing provides the most direct available readout of how well your body is aging relative to the Four Shadows of cardiovascular disease, cancer, neurodegenerative disease, and metabolic dysfunction.
The Elysium Index makes this measurement more accessible than it has ever been. At $299 with painless saliva collection, the barrier to entry is low enough that a broad population of health-conscious consumers can establish a biological age baseline and begin tracking the impact of the Five Pillars: Nutrition, Sleep, Movement, Breathwork, and Mindset.
The practical recommendation: if you are new to epigenetic testing and want to understand your biological age without a large financial commitment, the Elysium Index is a reasonable starting point. If you want maximum depth, algorithmic transparency, and the strongest research pedigree, TruDiagnostic TruAge Complete at $499 is the category leader. Regardless of which test you choose, the real value emerges from longitudinal tracking. Take a baseline, implement evidence-based lifestyle changes, and retest. The number that matters most is not your biological age on any single test; it is whether that number is moving in the right direction over time.
Frequently Asked Questions
How does the Elysium Index differ from TruDiagnostic TruAge?
The Elysium Index ($299) provides a biological age estimate, pace of aging, and cumulative rate of aging from a saliva sample. TruDiagnostic TruAge Complete ($499) uses a blood sample and provides multiple named algorithms (OMICmAge, DunedinPACE, GrimAge, PhenoAge, Horvath), organ-specific ages, and immune cell composition. TruDiagnostic offers greater depth and algorithmic transparency; Elysium offers a lower price and simpler collection process.
Is the Elysium Index accurate?
The Elysium Index uses DNA methylation analysis processed in a CLIA-certified laboratory, which provides analytical quality assurance. However, all epigenetic clocks carry a standard error of approximately 3 to 5 years at the individual level. This means a reported biological age should be understood as an estimate within a range, not a precise measurement. The test’s greatest accuracy comes from longitudinal tracking, where the direction of change is more reliable than any single absolute number.
Do I need to buy Elysium supplements to use the Index test?
No. The Elysium Index functions independently of the company’s supplement products. Users can purchase and use the biological age test without buying Basis or any other Elysium supplement. The test provides biological age data that can be used to track the impact of any lifestyle intervention, whether related to Elysium’s products or not.
Why does the Elysium Index use saliva instead of blood?
Saliva collection is painless and requires no finger-prick blood draw, making it more accessible for a broader consumer audience. Saliva has been validated as a viable sample type for DNA methylation analysis. However, blood-based analysis (used by TruDiagnostic, GlycanAge, and myDNAge) is generally considered more standardized due to lower cellular heterogeneity. The trade-off is convenience versus analytical consistency.
How often should I retest with the Elysium Index?
Elysium recommends retesting every 3 to 6 months to track the impact of lifestyle changes over time. At $299 per test, users planning regular monitoring should budget approximately $600 to $1,200 annually. The first test establishes a baseline; subsequent tests reveal whether interventions in nutrition, sleep, exercise, and stress management are producing measurable changes in biological aging rate.
Similar Posts
Muscle Is a Longevity Organ: What the Science of Strength Training Reveals About All-Cause Mortality
Grip strength outperforms blood pressure as a mortality predictor. A 2022 BMJ meta-analysis found that 30 to 60 minutes of resistance training per week cuts all-cause mortality by 15 percent….
Oura Ring 5 Price and Blood Pressure Signals: What $399 Actually Buys You
The Oura Ring 5 starts at $399 and ships with overnight blood pressure signals. It is not FDA cleared, and the reason why is a rule change most coverage skipped.
Tim Ferriss’s Health and Longevity Stack: The Biohacker Who Got More Conservative
Tim Ferriss’s current health and longevity stack is less extreme than many expect: sleep, exercise, food quality, creatine, vitamin D, metabolic experiments, mitochondrial health, and cautious interest in rapamycin, ketones,…
First-in-Class Bispecific ADC Rewrites the Rules for Triple-Negative Breast Cancer at ASCO 2026
At ASCO 2026, izalontamab brengitecan became the first bispecific antibody-drug conjugate to improve both progression-free and overall survival in triple-negative breast cancer. Inside the EGFRxHER3 mechanism, the Phase 3 trial…
The Daily Rounds: Longevity & Health Care Brief | May 18, 2026
🧠 Brain Choline Deficit Drives Anxiety — A 25-study meta-analysis finds 8% lower brain choline in anxiety disorder patients, the first chemical brain pattern clearly linked to anxiety. ❤️ Inflammation Cuts Cardiac Events by 31% — Scientific American confirms chronic inflammation is a primary heart disease driver and colchicine reduces events by nearly a third in clinical trials. 🔬 First Epigenetic Reprogramming Trial Enters Humans — FDA clearance of ER-100 marks the first human test of partial epigenetic reprogramming to rejuvenate aged tissue. 🦠 Gut Microbiome Redirects Amino Acids Against Cancer — Weill Cornell research shows microbiome composition determines whether dietary asparagine feeds tumors or boosts immune defense. 🥗 Meal Timing Amplifies Exercise Metabolic Benefits — A 19-RCT meta-analysis confirms time-restricted eating plus exercise outperforms exercise alone for fat loss and cardiometabolic health.
The AI Second Reader That Changed the Chart
A large liver-cancer study shows what happened after an AI system found overlooked lesions: reports changed, cases escalated, and care pathways moved—without yet proving better patient outcomes.
